65,437 trials
Inflammation Eye Pain · Postoperative Cataract
Primary: Absence of Anterior Chamber Cells at Visit 6. — 57.2; 24.0 percentage of study eyes — p=<0.0001
POSTOPERATIVE DELIRIUM · POSTOPERATIVE COGNITIVE DECLINE
Primary: Delirium — 5; 6; 5; 6 Participants
Metastatic Lung Non-Small Cell Carcinoma · Recurrent Lung Non-Small Cell Carcinoma · Stage IV Lung Cancer AJCC v8
Primary: Overall Response Rate — 0 percentage of participants
Neoplasms
Primary: Maximum Tolerated Dose (MTD) or Relevant Biological Dose (RBD) of BI 836845 During the First Treatment Course of the Dose Escalation Phase — 1000 mg
Smoking Behaviors · Smoking, Cigarette
Primary: Mean Change From Baseline in 4-item Questionnaire on Smoking Urges Craving Score During Cue Reactivity to Personal Cues — -36.5; -36.3; -36.6; -22.2 score on a scale…
Recurrent High Grade Meningioma
Primary: Progression Free Survival (PFS) — 4.17; 2.43 Months — p=0.204
Preeclampsia Postpartum
Primary: Cutaneous Conductance (%Maximum) Response to Acetylcholine — 89.4; 72.5 % of maximal cutaneous conductance
HIV · Pregnancy
Primary: Number of Participants Receiving Complete PMTCT — 60; 22 Participants
Seasonal Influenza
Primary: Geometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibody Levels as Measured by Hemagglutination Inhibition (HAI) — 147.49; 220.17; 137.90; 208.10 titer
Community Health Aides · Industrial Hygiene · Volatile Organic Compounds
Primary: Change in Volatile Organic Chemical Concentrations From Pre- to Post-Intervention — 2738; 3875; 523; 225 ppb
Lymphoma, Non-Hodgkin
Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296
Excessive Ear Wax
Primary: Skin Irritation — 0.22; 0.20; 0.13; 0.11 score on a scale
Advanced Renal Cell Carcinoma
Primary: 1-year Progression Free Survival (PFS) Rate for ccRCC Patients — 34.6; 53.8; 33.3; 75 Percentage of participants
Sleep Disordered Breathing
Primary: Adherence to Positive Airway Pressure (PAP) Therapy — 4; 3.5 hours per night
Diabetic Macular Edema · Diabetic Retinopathy
Primary: Time to Worsening of DME Disease Activity in the Study Eye. — 82.1; 96.1; 19.1 Weeks